Ipsen Bylvay Fails Phase 3 BOLD in Biliary Atresia

Ipsen (Euronext Paris: IPN; ADR: IPSEY) announced on July 24, 2026 that the Phase 3 BOLD trial of Bylvay (odevixibat) in pediatric biliary atresia did not meet its primary endpoint of improvement in native liver survival versus placebo at week 104. This was the first global Phase 3 trial ever conducted in biliary atresia, the leading cause of pediatric liver transplantation worldwide.

The IPSEY ADR closed at $44.81 on July 24 with volume of just 229 shares, reflecting the thin OTC trading typical of foreign pharma ADRs. Most trading occurs on Euronext Paris under IPN. Ipsen is not a US-listed company, so there is no direct US ticker to track for most biotech investors.

What the trial showed

BOLD (NCT04336722) enrolled 254 patients across 19 countries. Children who had already undergone a Kasai hepatoportoenterostomy, the surgical procedure used to restore bile flow in biliary atresia, received oral odevixibat 120 mcg/kg/day or placebo once daily for up to 104 weeks. The primary endpoint was native liver survival, defined as time from randomization to first occurrence of liver transplant or death at week 104. Bylvay did not improve native liver survival compared to placebo. Safety was in line with the established profile of odevixibat in its approved indications.

Why this matters

Biliary atresia is a rare pediatric cholestatic liver disease where bile builds up in the liver, causing progressive inflammation, fibrosis, cirrhosis, and ultimately liver failure if untreated. Many children develop severe liver damage and require transplant before age 2. There are no approved medical treatments beyond surgery and transplant. The Kasai procedure buys time but does not cure the disease.

Bylvay is an ileal bile acid transport (IBAT) inhibitor. It works by blocking the reabsorption of bile acids in the intestine, diverting them to be excreted in feces instead. The logic for testing it in biliary atresia was that reducing bile acid reabsorption was hypothesized to lessen the cholestatic injury driving liver damage. That hypothesis did not translate into a survival benefit.

Commercial impact

Bylvay is already approved for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome pruritus, but the franchise has struggled commercially. The biliary atresia expansion was the most significant near-term growth lever for the drug. Without it, Bylvay’s commercial ceiling remains limited to current indications. Ipsen will continue to analyze subgroup data from the BOLD dataset, but the company explicitly stated the results reflect the significant challenge biliary atresia presents.

IBAT class divergence

The miss stands in contrast to GSK’s Lynavoy (linerixibat), also an IBAT inhibitor, which received a positive CHMP opinion for cholestatic pruritus in primary biliary cholangitis on July 24. The IBAT inhibitor class is having divergent outcomes across different cholestatic diseases: effective for pruritus symptoms in PBC and PFIC, but ineffective at modifying disease progression in biliary atresia. This is a reminder that mechanism does not guarantee outcomes across indications.

The risk for Ipsen shareholders is that the pipeline catalyst is gone and Bylvay’s growth story narrows. For a framework on interpreting clinical trial failures and what they mean for drug pipelines, see our guide to reading a clinical trial press release.

Sources: Ipsen press release, ClinicalTrials.gov (BOLD: NCT04336722).

What It Means for the Trade

For IPSEY holders the read is direct: the Bylvay growth story just lost its biggest lever, and the franchise re-rates to its approved-indication run rate in PFIC and Alagille pruritus. Ipsen trades primarily on Euronext Paris (IPN) with a thin ADR, so the repricing happens in Paris — but the strategic implications are universal. BOLD was the first global Phase 3 ever run in biliary atresia, and its failure is a class-level signal: any company eyeing this indication now faces evidence that a 254-patient, 104-week native-liver-survival endpoint was not met by the mechanism that made the most biological sense. The one tradable wrinkle: subgroup analyses from the BOLD dataset are coming — treat that as optionality, not a thesis. The cleaner near-term read is on the IBAT class itself, where GSK’s linerixibat CHMP opinion in PBC pruritus the same week marks the divergent path: symptom relief is achievable, disease modification is not.

Mechanism and Market Context

Biliary atresia is a newborn obstructive cholangiopathy — bile ducts fail to develop or scar shut in the first weeks of life, bile backs up, and the liver fibroses toward failure, making it the leading indication for pediatric transplant worldwide. The Kasai procedure reconnects bile drainage surgically, but success decays and most children still face transplantation. Odevixibat blocks the ileal bile acid transporter, cutting enterohepatic recirculation so bile acids exit in feces rather than returning to an already-cholestatic liver — a rational hypothesis for reducing toxic bile-acid exposure. The BOLD failure suggests the injury cascade is driven more by the obstructive and inflammatory architecture of the disease than by circulating bile-acid load, which is why the same drug works for pruritus in PFIC and Alagille but could not move survival here.

Risks and What Could Go Wrong

1. For Ipsen: the pipeline catalyst is gone, and Bylvay’s commercial struggles in approved indications now define the ceiling — watch for guidance language and any strategic review of the hepatology franchise.
2. Subgroup hope can trap capital: a post-hoc signal is not a trial, and the base rate for salvaging a missed primary endpoint in pediatric liver disease is poor.
3. For the IBAT class: the biliary atresia door is now closed for the foreseeable future, and pruritus-only indications carry smaller ceilings.